These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22975372)

  • 41. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications.
    Hoos A; Levey DL
    Expert Rev Vaccines; 2003 Jun; 2(3):369-79. PubMed ID: 12903802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunotherapy of renal cell carcinoma.
    Gouttefangeas C; Stenzl A; Stevanović S; Rammensee HG
    Cancer Immunol Immunother; 2007 Jan; 56(1):117-28. PubMed ID: 16676181
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.
    Volk J; Sel S; Ganser A; Schöffski P
    Curr Drug Targets; 2002 Oct; 3(5):401-8. PubMed ID: 12182231
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
    Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer.
    Lemoine FM; Cherai M; Giverne C; Dimitri D; Rosenzwajg M; Trebeden-Negre H; Chaput N; Barrou B; Thioun N; Gattegnio B; Selles F; Six A; Azar N; Lotz JP; Buzyn A; Sibony M; Delcourt A; Boyer O; Herson S; Klatzmann D; Lacave R
    Int J Oncol; 2009 Sep; 35(3):569-81. PubMed ID: 19639177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vaccines in renal cell carcinoma.
    Kübler H; Vieweg J
    Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapeutic approaches for renal cancer.
    Pizza G; de Vinci C; Viza D
    Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
    [No Abstract]   [Full Text] [Related]  

  • 53. Melanoma vaccines: mixed past, promising future.
    Ozao-Choy J; Lee DJ; Faries MB
    Surg Clin North Am; 2014 Oct; 94(5):1017-30, viii. PubMed ID: 25245965
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.
    Tykodi SS
    Immunotherapy; 2013 Jun; 5(6):607-19. PubMed ID: 23725284
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
    Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
    J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor vaccination using peptide based vaccines.
    Eisenbach L; Bar-Haim E; El-Shami K
    Immunol Lett; 2000 Sep; 74(1):27-34. PubMed ID: 10996624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Personalized cancer vaccines: adjuvants are important, too.
    Gouttefangeas C; Rammensee HG
    Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110.
    Kim HL; Sun X; Subjeck JR; Wang XY
    Cancer Immunol Immunother; 2007 Jul; 56(7):1097-105. PubMed ID: 17146628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer.
    Ranieri E; Gigante M; Storkus WJ; Gesualdo L
    Clin Exp Immunol; 2007 Mar; 147(3):395-400. PubMed ID: 17302887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.